The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Aberrant wound-healing responses to injury have been implicated in the development of pulmonary fibrosis, but the mediators directing these pathologic responses have yet to be fully identified. We show that lysophosphatidic acid levels increase in bronchoalveolar lavage fluid following lung injury in the bleomycin model of pulmonary fibrosis, and that mice lacking one of its receptors, LPA1, are markedly protected from fibrosis and mortality in this model. The absence of LPA1 led to reduced fibroblast recruitment and vascular leak, two responses that may be excessive when injury leads to fibrosis rather than to repair, whereas leukocyte recruitment was preserved during the first week after injury. In persons with idiopathic pulmonary fibrosis, lysophosphatidic acid levels in bronchoalveolar lavage fluid were also increased, and inhibition of LPA1 markedly reduced fibroblast responses to the chemotactic activity of this fluid. LPA1 therefore represents a new therapeutic target for diseases in which aberrant responses to injury contribute to fibrosis, such as idiopathic pulmonary fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bexotegrast is a small molecule dual inhibitor of αvβ6 and αvβ1[105]. Cumulative data of 630 patients composed of several phase 1 and 2 trials investigating αvβ6 and αvβ1 in both IPF and primary sclerosing cholangitis demonstrated mild adverse effects in the bexotegrast group (headache, diarrhea, and nausea), with diarrhea being the most common in phase 2 studies”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [104]
In the citing paper
“In pulmonary fi brosis, lysophosphatidic acid receptor 1 (LPA1) activation is associated with fi broblast recruitment, activation/proliferation, and survival, as well as epithelial cell apoptosis, all of which drive lung fi brosis progression (8, 9).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“LPA1 is known to be involved in in fl ammatory responses of vascular endothelium and fi broblast recruitment”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
In the citing paper
“and LPA1 de fi ciency attenuated fi broblast recruitment in a murine model of lung fi brosis (8).”
From Efficacy and Safety of Admilparant, an LPA1 Antagonist, in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial. (2025) · cites this paper as [8]
Citations
Cites
Wound Healing--Aiming for Perfect Skin Regeneration
Martin, P. (1997) · Science · doi:10.1126/science.276.5309.75 · Cited by 4,804 · cited 1×
“After cutaneous injury, fibroblasts migrate into the provisional fibrin matrix of the wound clot during granulation tissue formatio”
BackgroundRidley, A. J., & Hall, A. (1992) · Cell · doi:10.1016/0092-8674(92)90163-7 · Cited by 4,468
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Chemokines — Chemotactic Cytokines That Mediate Inflammation
Luster, A. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802123380706 · Cited by 3,630 · cited 1×
“1a ), indicating that the relevant fibroblast receptor(s) signal through the Gα i class of G proteins, a hallmark of the chemoattractant subfamily of GPCR”
BackgroundSelf-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
The epigenetic progenitor origin of human cancer
Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1748 · Cited by 1,853 · cited 1×
“Epigenetic processes, such as DNA or histone methylation and histone acetylation, produce heritable but potentially reversible changes in DNA or its associated proteins, and are prominent in developmental processes and oncogenesis ( 1 ).”
BackgroundSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786 · cited 1×
“In the lung, aberrant wound-healing responses to injury are thought to contribute to the pathogenesis of idiopathic pulmonary fibrosis (IPF”
BackgroundSelf-citationCirculating Fibrocytes Define a New Leukocyte Subpopulation That Mediates Tissue Repair
Bucala, R., Spiegel, L. A., Chesney, J., Hogan, M., & Cerami, A. (1994) · Molecular Medicine · doi:10.1007/bf03403533 · Cited by 1,308
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257 · cited 1×
“Fibrin deposition in injured airspaces may contribute to fibroblast accumulation both by providing a provisional matrix for fibroblast migration and by promoting epithelial-to-mesenchymal transitio”
BackgroundThe emerging role of lysophosphatidic acid in cancer
Mills, G. B., & Moolenaar, W. H. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1143 · Cited by 1,094 · cited 1×
“LPA has been shown to induce the invasion of cancer cells across tissue barriers, promoting metastasi”
Background
Cited by
Items 201–300 of 857
Into the matrix: targeting fibroblasts in pulmonary fibrosis
Sivakumar, P., Ntolios, P., Jenkins, G. R., & Laurent, G. J. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328356800f · Cited by 74
“466 signalling by IL13 and IL17 results in the production of inflammatory mediators such as IL6 and IL8 and thrombin-mediated signalling results in the production of CCL2 [30,43].”
BackgroundInfluentialHe, D., Su, Y., Usatyuk, P. V., Spannhake, E. W., Kogut, P., Solway, J., Natarajan, V., & Zhao, Y. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.007393 · Cited by 66
Smyth, S. S., Mueller, P., Yang, F., Brandon, J. A., & Morris, A. J. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302737 · Cited by 67
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver Fibrosis
Bain, G., Shannon, K. E., Huang, F., Darlington, J. V., Goulet, L., Prodanovich, P., Gina, L. P., Santini, A. M., Stein, A. J., Lonergan, D., et al. (2016) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.237156 · Cited by 65
“LPA-LPA1 signaling has been shown to contribute to the pathogenesis of fibrosis inmultiple organ systems, including the lung, kidney, skin, and peritoneum (Pradere et al., 2007, 2008; Tager et al., 2008; Swaney et al., 2010, 2011; Castelino et al., 2011; Sakai et al., 2013).”
BackgroundInsights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast
Reininger, D., Wolf, F., Mayr, C. H., Wespel, S. L., Laufhaeger, N., Geillinger‐Kästle, K. E., Dick, A., Gantner, F., Nickolaus, P., & Herrmann, F. E. (2025) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0614oc · Cited by 69
The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis
Magkrioti, C., Oikonomou, N., Kaffe, E., Mouratis, M.-A., Xylourgidis, N., Barbayianni, I., Megadoukas, P., Harokopos, V., Valavanis, C., Chun, J. J. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3797 · Cited by 69
“Cancer Res; 78(13) July 1, 2018 Cancer Research 3636”
BackgroundResultInfluentialSelf-citationMetabolic reprogramming of pulmonary fibrosis
Li, J., Zhai, X., Sun, X., Cao, S., Yuan, Q., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1031890 · Cited by 77
“LPA is a key metabolic molecule involved in the de novo biosynthesis of phospholipids, causes an increase in bronchoalveolar lavage (BAL) fluid levels in IPF patients compared with the controls (Tager et al., 2008; Natarajan et al., 2013).”
BackgroundRole of sphingosine 1-phosphate and lysophosphatidic acid in fibrosis
Pyne, N. J., Dubois, G. R., & Pyne, S. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.07.003 · Cited by 65
Ma, L., Nagai, J., Chun, J. J. M., & Ueda, H. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-29 · Cited by 63
“; licensee BioMed Central Ltd Commons Attribution License (http://creativec reproduction in any medium, provided the or growth, have been well-documented [8-12].”
BackgroundSelf-citationEpigenetic regulation of diacylglycerol kinase alpha promotes radiation-induced fibrosis
Weigel, C., Veldwijk, M. R., Oakes, C. C., Seibold, P., Slynko, A., Liesenfeld, D. B., Rabionet, M., Hanke, S., Wenz, F. K., Sperk, E., et al. (2016) · Nature Communications · doi:10.1038/ncomms10893 · Cited by 68
Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice
Li, H. Y., Oh, Y. S., Choi, J.-W., Jung, J. Y., & Jun, H. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.010 · Cited by 63
Multiple actions of lysophosphatidic acid on fibroblasts revealed by transcriptional profiling
Stortelers, C., Kerkhoven, R. M., & Moolenaar, W. H. (2008) · BMC Genomics · doi:10.1186/1471-2164-9-387 · Cited by 65
“LPA has long been known to stimulate the proliferation and migration of fibroblasts [1,11], while excessive LPA signaling in these cells can lead to fibrosis [12].”
BackgroundKawaguchi, M., Okabe, T., Okudaira, S., Nishimasu, H., Ishitani, R., Kojima, H., Nureki, O., Aoki, J., & Nagano, T. (2013) · ACS Chemical Biology · doi:10.1021/cb400150c · Cited by 62
Lysophosphatidic Acid Receptors: Biochemical and Clinical Implications in Different Diseases
Xiang, H., Lu, Y., Shao, M., & Wu, T. (2020) · Journal of Cancer · doi:10.7150/jca.41841 · Cited by 65
“In previous studies, LPA levels were remarkably elevated in bronchoalveolar lavage (BAL) fluid collected from patients with idiopathic pulmonary fibrosis (IPF) compared to the normal control group [120,121].”
BackgroundCheng, P. T. W., Kaltenbach, R. F., Zhang, H., Shi, J., Tao, S., Li, J., Kennedy, L. J., Walker, S. J., Shi, Y., Wang, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01256 · Cited by 61
Niacin Attenuates Pulmonary Hypertension Through H-PGDS in Macrophages
Jia, D., Bai, P., Wan, N., Liu, J., Zhu, Q., He, Y., Chen, G., Wang, J., Chen, H., Wang, C., et al. (2020) · Circulation Research · doi:10.1161/circresaha.120.316784 · Cited by 64
Fujimori, N., Umemura, T., Kimura, T., Tanaka, N., Sugiura, A., Yamazaki, T., Joshita, S., Komatsu, M., Usami, Y., Sano, K., et al. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i11.1239 · Cited by 62
Role of Adenosine Signaling in Penile Erection and Erectile Disorders
Phatarpekar, P. V., Wen, J., & Xia, Y. (2009) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2009.01555.x · Cited by 69
“A1 and A3 couple to inhibitory G-protein, Gi, to inhibit adenylyl cyclase that results in decreased cyclic AMP [30] levels, intracellularly.”
BackgroundLiang, J., Jung, Y., Tighe, R. M., Xie, T., Liu, N., Leonard, M., Gunn, M. D., Jiang, D., & Noble, P. W. (2012) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00256.2011 · Cited by 63
“While WT littermates died after bleomycin treatment at a rate similar to previous reports (45), all Ccl2 transgenic mice survived bleomycin challenges at 5 U/kg (Fig.”
Therapeutic pro-fibrogenic signaling pathways in fibroblasts
Cannito, S., Novo, E., & Parola, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.017 · Cited by 62
“As a further example, in IPF the list of other peptide mediators proposed to stimulate lung MFs to proliferate (i.e., in addition to PDGF), can include members of the IL-6 family (IL-6, IL-11 and oncostatin M or OSM) and CCL21 through the CCR7 receptor (reviewed in ref.”
BackgroundResultInfluentialAlveolar fibroblasts in acute lung injury: biological behaviour and clinical relevance
Quesnel, C., Nardelli, L., Piednoir, P., Leçon-Malas, V., Marchal-Sommé, J., Lasocki, S., Bouadma, L., Philip, I., Soler, P., Crestani, B., et al. (2009) · European Respiratory Journal · doi:10.1183/09031936.00074709 · Cited by 60
Corte, T. J., Lancaster, L., Swigris, J. J., Maher, T. M., Goldin, J. G., Palmer, S. M., Suda, T., Ogura, T., Minnich, A., Zhan, X., et al. (2021) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2021-001026 · Cited by 59
Huang, L. S., Mathew, B., Li, H., Zhao, Y., Ma, S., Noth, I., Reddy, S. P., Harijith, A. K., Usatyuk, P. V., Berdyshev, E. V., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201310-1917oc · Cited by 62
“Although the etiology of IPF remain unknown, a variety of factors including TGF-b (37), matrix metalloproteinases (38), arachidonic acid metabolites (39), NOX4 (40), LPA/LPA1 and 2 (7, 30), sphingosine kinase/S1P signaling axis (10), b-arrestin (41), and caspase 1 (42) have all been implicated in the pathogenesis of p…”
BackgroundQian, Y., Hamilton, M., Sidduri, A., Gabriel, S. D., Ren, Y., Peng, R., Kondru, R. K., Narayanan, A., Truitt, T., Hamid, R., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301022v · Cited by 66
Stearic acid attenuates profibrotic signalling in idiopathic pulmonary fibrosis
Kim, H., Yoo, H. J., Lee, K. M., Song, H. E., Kim, S. J., Lee, J. O., Hwang, J. J., & Song, J. W. (2020) · Respirology · doi:10.1111/resp.13949 · Cited by 59
David, M., Machuca‐Gayet, I., Kikuta, J., Ottewell, P. D., Mima, F., Leblanc, R., Bonnelye, E., Ribeiro, J., Holen, I., López‐Vales, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.533232 · Cited by 58
Self-citationPulmonary fibrosis: Emerging diagnostic and therapeutic strategies
Selvarajah, B., Platé, M., & Chambers, R. C. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101227 · Cited by 57
Houben, A. J. S., van Wijk, X. V., van Meeteren, L. V., van Zeijl, L., van de Westerlo, E. V. D., Hausmann, J., Fish, A., Perrakis, A., van Kuppevelt, T., & Moolenaar, W. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.358416 · Cited by 56
“ATX and LPA signaling play a vital role in embryonic development (5–7) and are implicated in a wide variety of physiological and pathological processes, as diverse as lymphocyte homing (8, 9), neurogenesis (10, 11), tumor progression (12–14), and fibrosis (15).”
BackgroundThe role of lipid-based signalling in wound healing and senescence
Pils, V., Terlecki‐Ζaniewicz, L., Schosserer, M., Grillari, J., & Lämmermann, I. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111527 · Cited by 60
“Indeed, in Hutchinson Gilford progeria syndrome cells and in vivo, scientist identified a decline in the LPA-receptor as a major contributor of the premature ageing phenotype (Chen et al., 2020).”
BackgroundInfluentialSphingosine-1-phosphate as a mediator involved in development of fibrotic diseases
Takuwa, Y., Ikeda, H., Okamoto, Y., Takuwa, N., & Yoshioka, K. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.06.008 · Cited by 63
“showed that LPA is a crucial factor in the progression of pulmonary fibrosis [51].”
BackgroundA Critical Role for the mTORC2 Pathway in Lung Fibrosis
Chang, W., Wei, K., Ho, L. A., Berry, G. J., Jacobs, S. S., Chang, C. H., & Rosen, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106155 · Cited by 56
“LPA appears to play a significant role in lung fibrosis, in part through its induction of fibroblast migration [36].”
BackgroundPopnikolov, N. K., Dalwadi, B. H., Thomas, J. D., Johannes, G. J., & Imagawa, W. T. (2012) · Tumor Biology · doi:10.1007/s13277-012-0485-1 · Cited by 56
Emo, J. A., Meednu, N., Chapman, T. J., Rezaee, F., Balys, M. M., Randall, T. D., Rangasamy, T., & Georas, S. N. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1102956 · Cited by 56
“By promoting fibroblast recruitment (25) and smooth muscle mitogenesis (58), local generation of LPA during cycles of airway injury and repair could lead to airway fibrosis and smooth muscle hypertrophy.”
BackgroundTargeting cancer-associated fibroblasts: Challenges, opportunities and future directions
Jenkins, B. H., Buckingham, J. F., Hanley, C. J., & Thomas, G. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108231 · Cited by 57
Wang, J., Jiang, M., Xiong, A., Zhang, L., Luo, L., Liu, Y., Liu, S., Qin, R., Wu, D., Xiong, Y., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106286 · Cited by 55
Old medications and new targeted therapies in systemic sclerosis
Nagaraja, V., Denton, C. P., & Khanna, D. (2014) · Rheumatology · doi:10.1093/rheumatology/keu285 · Cited by 57
Lee, S., Leoni, G., Neumann, P., Chun, J. J. M., Nusrat, A., & Yun, C. C. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00038-13 · Cited by 55
“Recently, LPA1 has been linked to pulmonary and renal fibrosis (50, 51), and clinical trials to test the efficacy of LPA1 inhibitors in treatment of fibrotic diseases are expected to follow.”
BackgroundSelf-citationTargeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis
Ma, H., Liu, S., Li, S., & Xia, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.918771 · Cited by 62
“Lysophosphatidic acid (LPA) has been proven to activate G protein-mediated signal transduction pathways by binding to its receptors (LPAR1 and LPAR2), which leads to different reactions from lung cells, including the promotion of the apoptosis of epithelial cells, regulation of endothelial permeability, activation of…”
BackgroundWnt Pathway in Pulmonary Fibrosis in the Bleomycin Mouse Model
Liu, L., Carron, B., Yee, H. T., Yie, T.-A., Hajjou, M., & Rom, W. N. (2009) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.v28.i2.20 · Cited by 57
Cabello‐Verrugio, C., Córdova, G., Vial, C., Zúñiga, L. M., & Brandan, E. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.10.019 · Cited by 57
FAK-Related Nonkinase Is a Multifunctional Negative Regulator of Pulmonary Fibrosis
Ding, Q., Cai, G.-Q., Hu, M., Yang, Y., Zheng, A., Tang, Q., Gladson, C. L., Hayasaka, H., Wu, H., You, Z., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.01.026 · Cited by 55
What have we learned from basic science studies on idiopathic pulmonary fibrosis?
Yanagihara, T., Sato, S., Upagupta, C., & Kolb, M. R. J. (2019) · European Respiratory Review · doi:10.1183/16000617.0029-2019 · Cited by 59
Knipe, R. S., Spinney, J. J., Abe, E. A., Probst, C. K., Franklin, A., Logue, A., Giacona, F., Drummond, M., Griffith, J., Brazee, P. L., et al. (2021) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2020-0408oc · Cited by 55
Self-citationKim, J. H., & Adelstein, R. S. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.22631 · Cited by 53
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis
Ninou, I., Kaffe, E., Müller, S., Budd, D. C., Stevenson, C. S., Ullmer, C., & Aidinis, V. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.08.003 · Cited by 53
Zhou, Y., Little, P. J., Ta, H. T., Xu, S., & Kamato, D. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107404 · Cited by 56
“The vascular leak produced by lung injury is markedly attenuated in LPAR1 knockoutmice (Tager et al., 2008).”
BackgroundAutotaxin Emerges as a Therapeutic Target for Idiopathic Pulmonary Fibrosis
Tager, A. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0235ed · Cited by 56
Self-citationAutotaxin in embryonic development
Moolenaar, W. H., Houben, A. J. S., Lee, S., & van Meeteren, L. A. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2012.09.013 · Cited by 54
Matralis, A. N., Afantitis, A., & Aidinis, V. (2018) · Medicinal Research Reviews · doi:10.1002/med.21551 · Cited by 52
Salgado-Polo, F., & Perrakis, A. (2019) · Cancers · doi:10.3390/cancers11101577 · Cited by 54
“Deregulation of the LPA signalling axis has been linked to different diseases, such liver disease [4], fibrosis [5], pruritus [6], multiple sclerosis [7], inflammation, and cancer [8,9].”
BackgroundLysophosphatidic acid (LPA) receptor modulators: Structural features and recent development
Bhagyalalitha, M., Pujar, G. V., Kumar, T. D. A., Akshatha, H. S., Sethu, A. K., Singh, M., Kanagarla, A., & Mathew, B. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113574 · Cited by 52
Effects of oral milk extracellular vesicles on the gut microbiome and serum metabolome in mice
Du, C., Quan, S., Nan, X., Zhao, Y., Shi, F., Luo, Q., & Xiong, B. (2021) · Food & Function · doi:10.1039/d1fo02255e · Cited by 54
Lysophosphatidic acid, a simple phospholipid with myriad functions
Yanagida, K., & Shimizu, T. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108421 · Cited by 51
Chow, L. N. Y., Schreiner, P., Ng, B. Y. Y., Lo, B. C., Hughes, M. R., Scott, R. W., Gusti, V., Lecour, S., Simonson, E., Manisali, I., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151765 · Cited by 53
Autotaxin inhibitors: a patent review (2012-2016)
Nikolaou, A. I., Kokotou, M. G., Limnios, D., Psarra, A., & Kokotos, G. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1323331 · Cited by 52
“IPF patients and a bleomycin (BLM) murine model [95].”
BackgroundOhmaru‐Nakanishi, T., Asanoma, K., Fujikawa, M., Fujita, Y., Yagi, H., Onoyama, I., Hidaka, N., Sonoda, K., & Kato, K. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.11.008 · Cited by 57
Gu, L., Deng, H., Ren, Z., Zhao, Y., Yu, S., Guo, Y., Dai, J., Chen, X., Li, K., Li, R., et al. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02491 · Cited by 57
A WISP1 antibody inhibits MRTF signaling to prevent the progression of established liver fibrosis
Xi, Y., LaCanna, R., N’Diaye, E.-N., Gierke, S., Ma, H., Caplazi, P., Sagolla, M. S., Huang, Z., Lucio, L., Arlantico, A., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.009 · Cited by 51
Adenosine signaling in normal and sickle erythrocytes and beyond
Zhang, Y., & Xia, Y. (2012) · Microbes and Infection · doi:10.1016/j.micinf.2012.05.005 · Cited by 56
“Within cells adenosine has multiple fates: 1) conversion to inosine via deamination, 2) conversion to adenosylhomocysteine (AdoHcy) via Sadenosylhomocytesine hydrolase (SAHH), or conversion to AMP by adenosine kinase (ADK).”
BackgroundInfluentialGelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis
Oikonomou, N., Thanasopoulou, A., Τzouvelekis, Α., Harokopos, V., Paparountas, T., Nikitopoulou, I., Witke, W., Karameris, A., Kotanidou, A. N., Bouros, D. E., et al. (2009) · Thorax · doi:10.1136/thx.2008.107946 · Cited by 51
Extracellular Lipids in the Lung and Their Role in Pulmonary Fibrosis
Burgy, O., Loriod, S., Beltramo, G., & Bonniaud, P. (2022) · Cells · doi:10.3390/cells11071209 · Cited by 51
“Lysophosphatidic acid (LPA) is a major bioactive phospholipid acting via G proteincoupled surface receptors, and it is involved in many illnesses, including cancer and fibrosis [52,125,126].”
BackgroundMeinecke, A., Nagy, N., D’Amico, G., Kirmse, S., Klose, R., Schrödter, K., Zimmermann, A., Helfrich, I., Rundqvist, H., Theegarten, D., et al. (2012) · Blood · doi:10.1182/blood-2011-12-396895 · Cited by 50
Sphingolipid Regulation of Tissue Fibrosis
Shea, B. S., & Tager, A. M. (2012) · The Open Rheumatology Journal · doi:10.2174/1874312901206010123 · Cited by 53
“In support of this approach, multiple investigations in animal models of lung fibrosis have demonstrated that targeting one or more of these wound-healing responses can prevent the development of fibrosis, and in some cases reverse established fibrosis [30-36].”
BackgroundSelf-citationTargeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?
Rangarajan, S., Locy, M. L., Luckhardt, T., & Thannickal, V. J. (2016) · Drugs · doi:10.1007/s40265-015-0523-6 · Cited by 56
Black, K. E., Berdyshev, E. V., Bain, G., Castelino, F. V., Shea, B. S., Probst, C. K., Fontaine, B. A., Bronova, I. A., Goulet, L., Lagares, D., et al. (2016) · The FASEB Journal · doi:10.1096/fj.201500197r · Cited by 53
“In humans, LPA levels are increased in the BAL fluid of patients with IPF, compared with control subjects (10), and LPA is responsible for most of the fibroblast chemoattractant activity thatwas observed in the BAL fluid recovered from these patients (10, 13).”
BackgroundResultSelf-citationLow-Concentration Ozone Reacts with Plasmalogen Glycerophosphoethanolamine Lipids in Lung Surfactant
Wynalda, K., & Murphy, R. C. (2009) · Chemical Research in Toxicology · doi:10.1021/tx900306p · Cited by 49
Takagi, S., Sasaki, Y., Koike, S., Takemoto, A., Seto, Y., Haraguchi, M., Ukaji, T., Kawaguchi, T., Sugawara, M., Saito, M., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01956-6 · Cited by 53
“Several LPAR1 antagonists have recently been evaluated in clinical trials for treating idiopathic pulmonary fibrosis and diffuse cutaneous systemic sclerosis [39, 40], considering that the LPA and LPAR1 roles have been demonstrated in animal models and patients [44, 45].”
BackgroundDefining the mechanism of galectin-3–mediated TGF-β1 activation and its role in lung fibrosis
Calver, J., Parmar, N. R., Harris, G., Lithgo, R. M., Stylianou, P., Zetterberg, F. R., Gooptu, B., MacKinnon, A. C., Carr, S. B., Borthwick, L. A., et al. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.107300 · Cited by 50
Autotaxin and Endotoxin-Induced Acute Lung Injury
Mouratis, M.-A., Magkrioti, C., Oikonomou, N., Katsifa, A., Prestwich, G. D., Kaffe, E., & Aidinis, V. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133619 · Cited by 48
“Accordingly, genetic deletion of ATX, LPAR1 or LPAR2 [18, 20, 31], as well as pharmacologic inhibition of ATX or LPAR1[18, 19], attenuated the development of the bleomycin (BLM)-induced modelled disease.”
BackgroundInfluentialPolyunsaturated Lysophosphatidic Acid as a Potential Asthma Biomarker
Ackerman, S. J., Park, G. Y., Christman, J. W., Nyenhuis, S. M., Berdyshev, E. V., & Natarajan, V. (2016) · Biomarkers in Medicine · doi:10.2217/bmm.15.93 · Cited by 48
Meng, G., Tang, X., Yang, Z., Benesch, M. G. K., Marshall, A., Murray, D. L., Hemmings, D. G., Wuest, F. R., McMullen, T. P. W., & Brindley, D. N. (2017) · The FASEB Journal · doi:10.1096/fj.201700159r · Cited by 48
New Therapies for the Treatment of Renal Fibrosis
Liu, F., & Zhuang, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8871-2_31 · Cited by 51
Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis
Velagacherla, V., Mehta, C. H., Nayak, Y., & Nayak, U. Y. (2022) · Life Sciences · doi:10.1016/j.lfs.2021.120283 · Cited by 50
Smith, M. J. P., Lawler, M. J., Kopp, N., McLeod, D. D., Davulcu, A. H., Lin, D., Katipally, K. R., & Sfouggatakis, C. (2017) · Organic Process Research & Development · doi:10.1021/acs.oprd.7b00301 · Cited by 47
Discovery of BI-2545: A Novel Autotaxin Inhibitor That Significantly Reduces LPA Levels in Vivo
Kuttruff, C. A., Ferrara, M., Bretschneider, T., Hoerer, S., Handschuh, S., Nosse, B., Romig, H., Nicklin, P. L., & Roth, G. J. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00312 · Cited by 50
T‐cell positioning by chemokines in autoimmune skin diseases
Richmond, J. M., Strassner, J. P., Essien, K. I., & Harris, J. E. (2019) · Immunological Reviews · doi:10.1111/imr.12762 · Cited by 53
Regulation of blood and vascular cell function by bioactive lysophospholipids
Morris, A. J., Panchatcharam, M., Cheng, H., Federico, L., Fulkerson, Z., Selim, S., Miriyala, S., Escalante‐Alcalde, D., & Smyth, S. S. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03405.x · Cited by 46
Albright, R. A., Ornstein, D. L., Cao, W., Chang, W. C., Robert, D., Tehan, M., Hoyer, D., Liu, L., Stabach, P. R., Yang, G., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.505867 · Cited by 46
“The NPP family is implicated in a variety of pathologic and physiologic processes, including tumor invasion and metastasis (13–16), inflammation (17), lung fibrosis (18) and angiogenesis (NPP2) (19, 20), tissue calcification and bone development (NPP1) (2, 21–23), and hemostasis and platelet aggregation (NPP4) (7).”
BackgroundAutotaxin facilitates selective LPA receptor signaling
Salgado-Polo, F., Borza, R., Matsoukas, M.-T., Marsais, F., Jagerschmidt, C., Waeckel, L., Moolenaar, W. H., Ford, P., Heckmann, B., & Perrakis, A. (2023) · Cell Chemical Biology · doi:10.1016/j.chembiol.2022.12.006 · Cited by 45
LPA3, a unique G protein-coupled receptor for lysophosphatidic acid
Hama, K., & Aoki, J. (2010) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.03.001 · Cited by 45
Fibrosis in systemic sclerosis: common and unique pathobiology
Bhattacharyya, S., Wei, J., Tourtellotte, W. G., Hinchcliff, M., Gottardi, C. J., & Varga, J. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s18 · Cited by 48
“Lysophosphatidic acid (LPA), generated from membrane phospholipids via hydrolysis, induces fibroblast chemotaxis and CTGF production [34].”
BackgroundOhashi, T., & Yamamoto, T. (2015) · Experimental Dermatology · doi:10.1111/exd.12752 · Cited by 45
Huan, C., Yang, T., Liang, J., Xie, T., Cheng, L., Liu, N., Kurkciyan, A., Mena, J. M., Wang, C., Dai, H., et al. (2015) · Scientific Reports · doi:10.1038/srep14910 · Cited by 45
Lipids - two sides of the same coin in lung fibrosis
Mamazhakypov, A., SCHERMULY, R. T., Schaefer, L., & Wygrecka, M. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.04.007 · Cited by 46
Brindley, D. N., Tang, X., Meng, G., & Benesch, M. G. K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165938 · Cited by 49
Seeliger, B., Carleo, A., Wendel‐Garcia, P. D., Fuge, J., Montes‐Worboys, A., Schuchardt, S., Molina‐Molina, M., & Prasse, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837680 · Cited by 44
“LPA mediates its effects via a range of receptors, most importantly LPAR1, contributing to profibrotic fibroblast activation (Tager et al., 2008), TGF-ß activation (Xu et al.”
BackgroundLPA 1 is essential for lymphatic vessel development in zebrafish
Lee, S., Chan, T., Chen, T., Liao, B., Hwang, P., & Lee, H. (2008) · The FASEB Journal · doi:10.1096/fj.08-106088 · Cited by 50
“3706 0892-6638/08/0022-3706 © FASEB ment and vascular leak ( 13 ).”
Plasma Soluble Receptor for Advanced Glycation End Products in Idiopathic Pulmonary Fibrosis
Manichaikul, A. W., Sun, L., Borczuk, A., Önengüt-Gümüşcü, S., Farber, E., Mathai, S. K., Zhang, W., Raghu, G., Kaufman, J. D., Stukovsky, K. H., et al. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-485oc · Cited by 46
Eraky, S. M., El‐Mesery, M., El-Karef, A. A., Eissa, L. A., & El-Gayar, A. M. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.064 · Cited by 43
Suryadevara, V., Huang, L., Kim, S.-J., Cheresh, P., Shaaya, M., Bandela, M., Fu, P., Feghali‐Bostwick, C. A., Paolo, G. D., Kamp, D. W., et al. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00320.2018 · Cited by 43
“Genetic deletion of LPA1 and LPA2 in mice or inhibition of ATX protected mice from bleomycin-induced pulmonary fibrosis (27, 47, 62).”
BackgroundGPCR-induced YAP activation sensitizes fibroblasts to profibrotic activity of TGFβ1
Zmajkovicova, K., Bauer, Y., Menyhart, K., Schnoebelen, M., Freti, D., Boucher, M., Renault, B., Studer, R. O., Birker, M., Klenk, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0228195 · Cited by 43
“LPA is implicated in the pathogenesis of scleroderma, lung and kidney fibrosis [25–28] with LPA 1 being the primary candidate mediating fibrotic effects [29, 30].”
Lei, H., Guo, M., Li, X., Jia, F., Li, C., Yu, Y., Cao, M., Jiang, N., Ma, E., & Zhai, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00506 · Cited by 45
Sun, X., Chen, E., Dong, R., Chen, W., & Hu, Y. (2014) · Life Sciences · doi:10.1016/j.lfs.2014.11.033 · Cited by 42
Therapeutic Potential of Autotaxin/Lysophospholipase D Inhibitors
Federico, L., Pamuklar, Z. N., Smyth, S. S., & Morris, A. J. (2008) · Current Drug Targets · doi:10.2174/138945008785132439 · Cited by 42
van der Aar, E., Desrivot, J., Dupont, S., Heckmann, B., Fieuw, A. M., Stutvoet, S., Fagard, L., de Wal, K. V., & Helmer, E. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1424 · Cited by 43
Roles for lysophosphatidic acid signaling in vascular development and disease
Smyth, S. S., Kraemer, M. P., Yang, L., Hoose, P. M. V., & Morris, A. J. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158734 · Cited by 45
Natural Product-Based Potential Therapeutic Interventions of Pulmonary Fibrosis
Hasan, M., Paul, N. C., Paul, S. K., Saikat, A. S. M., Akter, H., Mandal, M., & Lee, S. (2022) · Molecules · doi:10.3390/molecules27051481 · Cited by 46
“Fibroblast recruitment in the BLM model of fibrosis is conducted using lysophosphatidic acid (LPA) via the receptor LPA1, which causes an elevation in vascular permeability and subsequent lung injury [109].”
BackgroundBadri, L., & Lama, V. N. (2012) · Stem Cells · doi:10.1002/stem.1171 · Cited by 42
Challenges in accurate quantitation of lysophosphatidic acids in human biofluids
Onorato, J. M., Shipkova, P. A., Minnich, A., Aubry, A., Easter, J. A., & Tymiak, A. A. (2014) · Journal of Lipid Research · doi:10.1194/jlr.d050070 · Cited by 42
Gill, M. W., Murphy, B. J., Cheng, P. T. W., Sivaraman, L., Davis, M., & Lehman-McKeeman, L. (2022) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2022.115885 · Cited by 41
Metadata
- Authors
- Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., Hart, W. K., Pardo, A., Blackwell, T. S., Xu, Y., Chun, J., & Luster, A. D.
- Affiliations
- Harvard University (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Indiana University Indianapolis (US)
- Vanderbilt University (US)
- Universidad Nacional Autónoma de México (MX)
- Scripps Research Institute (US)
- Corresponding author
- Luster, Andrew D
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-12-09
- Volume
- 14
- Issue
- 1
- Pages
- 45-54
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2131032222
- Cited by
- 823
- References
- 54
- Citations by year
- 2026: 24 · 2025: 49 · 2024: 50 · 2023: 49 · 2022: 51 · 2021: 61 · 2020: 55 · 2019: 38 · 2018: 36 · 2017: 47 · 2016: 49 · 2015: 41 · 2014: 51 · 2013: 49 · 2012: 53
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Lung Association
- National Institutes of Health (5r01ca069212-18)
- National Institute of Mental Health (K02 MH01723, R01MH051699, K02MH001723, R01MH-51699)
- National Cancer Institute (R01CA69212, R01-CA89228, R01CA095042, R01CA089228)
- National Institute of Neurological Disorders and Stroke (R01NS048478)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- lysophosphatidic acid, LPA1 receptor, pulmonary fibrosis, idiopathic pulmonary fibrosis, lung injury, fibroblast recruitment, vascular leakage, bleomycin-induced fibrosis, bronchoalveolar lavage fluid, wound healing, chemotaxis, therapeutic target
- MeSH terms
- Animals, Bleomycin, Bronchoalveolar Lavage Fluid, Female, Fibroblasts, Leukocytes, Lung, Lysophospholipids, Male, Mice, Inbred C57BL, Models, Biological, Pulmonary Fibrosis, Mice, Knockout, Receptors, Lysophosphatidic Acid, Mice, Lung Injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.